Benzinga | Sep 21, 2021 05:31AM EDT

Needham Maintains Buy on Verrica Pharmaceuticals, Lowers Price Target to $20

Needham analyst Serge Belanger maintains Verrica Pharmaceuticals (NASDAQ:VRCA) with a Buy and lowers the price target from $22 to $20.